While the multiple attributes method gains ground and traditional lab methods improve, broad efforts are underway to determine biopharmaceuticals’ most significant critical quality attributes and enable real-time release. May 01, 2019 By Agnes Shanley BioPharm International Volume 32, Issue 5, pg 42–45 Ivan Traimak - stock.adobe.com As the biopharmaceutical industry matures, manufacturers continue to embrace automation and more modern approaches to process design, development, and control. The reality, however, is that working with biologics is several orders of magnitude more complicated than it is for small molecules. Proteins are subject to problems during post-translational modification (PTM), and may also degrade during storage. Problems can result when… Click Here For Complete Article Text
|
|||||||||||||||||||||||||||
| Application Sequencing | |||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||
| Company | Product | Process | Other Subjects | Event | Event Date | Location | Publication | Publication Date | Text Descriptor | ||||||||||||||||||
|
|
|
|
|
|
|
|||||||||||||||||||||